This is the low-cost Q&A for my retail friends who cannot afford the subscription fee. Welcome, both Hindi and English.
Request paid members not to participate in this, as there will be several exclusive updates—audible, presentation, and text-based, long format—in April.
Hi Sajal bhai ,
Intersting merger announcement for Kopran
My thoughts
On financial front …. For the additional 1.2 cr of shares increasing , you are getting 24 odd rupees of cash per share and and eps of 15.23 , which is for a.High margin business in an attractive diagnostic center.
My understanding is this business is big contract and maybe having a B2G or b2b focus … but margins are phenomenal and maybe with a bigger parent they may be able to expand footprint.
An added plus is now the all the businesses seem under one roof mgmt maybe more aligned longer term.
On combined front
Total turnover is 700-720 cr and market cap is 900 crs . So still avliable at 1.2 x which is low for a pharma co and lower for a diagnostic co.
Can we expect a perception and valuation re rating going forward ?
Any thoughts from your end would be appreciated
Dear Sajal Sir,
Thanks for your immense service that you do to the investor community.
Have tremendous respect for the clarity and transparency you provide.
Your Views on Syngene considering the recent change of management and recent acquisitions in US, as well does performance of Syngene have a detrimental hangover impact with Biocon promotor holding and with Biocon struggling ( and continued reduction in promotor holding not giving so much confidence..)
Have been holding and accumulating Syngence for the past 4 years ( slow and steady) and intend to hold for long term ( 10 Y plus)
Thank you
Regards
Ravi